Literature DB >> 9372207

The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist.

T Z Baram1, D T Chalmers, C Chen, Y Koutsoukos, E B De Souza.   

Abstract

Corticotropin releasing factor (CRF) is the key coordinator of the neuroendocrine and behavioral responses to stress. In the central nervous system, CRF excites select neuronal populations, and infusion of CRF into the cerebral ventricles of infant rats produces severe age-dependent limbic seizures. These seizures, like other CRF effects, result from activation of specific receptors. Both of the characterized members of the CRF receptor family (CRF1 and CRF2), are found in the amygdala, site of origin of CRF-induced seizures, and may therefore mediate these seizures. To determine which receptor is responsible for the excitatory effects of CRF on limbic neurons, a selective, non-peptide CRF1 antagonist was tested for its ability to abolish the seizures, in comparison to non-selective inhibitory analogues of CRF. Pretreatment with the selective CRF1 blocker (NBI 27914) increased the latency and decreased the duration of CRF-induced seizures in a dose-dependent manner. The higher doses of NBI 27914 blocked the behavioral seizures and prevented epileptic discharges in concurrent electroencephalograms recorded from the amygdala. The selective CRF1 blocker was poorly effective when given systemically, consistent with limited blood-brain barrier penetration. Urocortin, a novel peptide activating both types of CRF receptors in vitro, but with preferential affinity for CRF2 receptors in vivo, produced seizures with a lower potency than CRF. These limbic seizures, indistinguishable from those induced by CRF, were abolished by pretreatment with NBI 27914, consistent with their dependence on CRF1 activation. In summary, CRF induces limbic seizures in the immature rat, which are abolished by selective blocking of the CRF1 receptor. CRF1-messenger RNA levels are maximal in sites of seizure origin and propagation during the age when CRF is most potent as a convulsant. Taken together, these facts strongly support the role of the developmentally regulated CRF1 receptor in mediating the convulsant effects of CRF in the developing brain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9372207      PMCID: PMC3387933          DOI: 10.1016/s0006-8993(97)00759-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  41 in total

1.  Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.

Authors:  C Chen; R Dagnino; E B De Souza; D E Grigoriadis; C Q Huang; K I Kim; Z Liu; T Moran; T R Webb; J P Whitten; Y F Xie; J R McCarthy
Journal:  J Med Chem       Date:  1996-10-25       Impact factor: 7.446

2.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

Authors:  W Vale; J Spiess; C Rivier; J Rivier
Journal:  Science       Date:  1981-09-18       Impact factor: 47.728

3.  Febrile seizures: an appropriate-aged model suitable for long-term studies.

Authors:  T Z Baram; A Gerth; L Schultz
Journal:  Brain Res Dev Brain Res       Date:  1997-02-20

4.  Appetite-suppressing effects of urocortin, a CRF-related neuropeptide.

Authors:  M Spina; E Merlo-Pich; R K Chan; A M Basso; J Rivier; W Vale; G F Koob
Journal:  Science       Date:  1996-09-13       Impact factor: 47.728

5.  The effect of 'Astressin', a novel antagonist of corticotropin releasing hormone (CRH), on CRH-induced seizures in the infant rat: comparison with two other antagonists.

Authors:  T Z Baram; Y Koutsoukos; L Schultz; J Rivier
Journal:  Mol Psychiatry       Date:  1996-07       Impact factor: 15.992

6.  Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression.

Authors:  D T Chalmers; T W Lovenberg; E B De Souza
Journal:  J Neurosci       Date:  1995-10       Impact factor: 6.167

7.  Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor.

Authors:  J Vaughan; C Donaldson; J Bittencourt; M H Perrin; K Lewis; S Sutton; R Chan; A V Turnbull; D Lovejoy; C Rivier
Journal:  Nature       Date:  1995-11-16       Impact factor: 49.962

8.  Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease.

Authors:  D P Behan; S C Heinrichs; J C Troncoso; X J Liu; C H Kawas; N Ling; E B De Souza
Journal:  Nature       Date:  1995-11-16       Impact factor: 49.962

9.  Developmental profile of messenger RNA for the corticotropin-releasing hormone receptor in the rat limbic system.

Authors:  S Avishai-Eliner; S J Yi; T Z Baram
Journal:  Brain Res Dev Brain Res       Date:  1996-02-26

10.  Cloning and characterization of human urocortin.

Authors:  C J Donaldson; S W Sutton; M H Perrin; A Z Corrigan; K A Lewis; J E Rivier; J M Vaughan; W W Vale
Journal:  Endocrinology       Date:  1996-05       Impact factor: 4.736

View more
  31 in total

1.  Immunocytochemical distribution of corticotropin-releasing hormone receptor type-1 (CRF(1))-like immunoreactivity in the mouse brain: light microscopy analysis using an antibody directed against the C-terminus.

Authors:  Y Chen; K L Brunson; M B Müller; W Cariaga; T Z Baram
Journal:  J Comp Neurol       Date:  2000-05-08       Impact factor: 3.215

2.  How does metyrapone decrease seizures?

Authors:  C A Koch; S R Bornstein; K Pacak; G P Chrousos
Journal:  Neurosurg Rev       Date:  1998       Impact factor: 3.042

3.  Long-term, progressive hippocampal cell loss and dysfunction induced by early-life administration of corticotropin-releasing hormone reproduce the effects of early-life stress.

Authors:  K L Brunson; M Eghbal-Ahmadi; R Bender; Y Chen; T Z Baram
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

4.  Modulation of dendritic differentiation by corticotropin-releasing factor in the developing hippocampus.

Authors:  Yuncai Chen; Roland A Bender; Kristen L Brunson; Jörn K Pomper; Dimitri E Grigoriadis; Wolfgang Wurst; Tallie Z Baram
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-20       Impact factor: 11.205

Review 5.  Hippocampal neuroplasticity induced by early-life stress: functional and molecular aspects.

Authors:  Kristina A Fenoglio; Kristen L Brunson; Tallie Z Baram
Journal:  Front Neuroendocrinol       Date:  2006-04-17       Impact factor: 8.606

Review 6.  Exposure to prenatal psychobiological stress exerts programming influences on the mother and her fetus.

Authors:  Curt A Sandman; Elysia P Davis; Claudia Buss; Laura M Glynn
Journal:  Neuroendocrinology       Date:  2011-04-15       Impact factor: 4.914

7.  Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis.

Authors:  Kendall M Carlin; Wylie W Vale; Tracy L Bale
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

8.  Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes.

Authors:  E Keen-Rhinehart; V Michopoulos; D J Toufexis; E I Martin; H Nair; K J Ressler; M Davis; M J Owens; C B Nemeroff; M E Wilson
Journal:  Mol Psychiatry       Date:  2008-08-12       Impact factor: 15.992

Review 9.  Neuropeptide-mediated excitability: a key triggering mechanism for seizure generation in the developing brain.

Authors:  T Z Baram; C G Hatalski
Journal:  Trends Neurosci       Date:  1998-11       Impact factor: 13.837

10.  Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress.

Authors:  Sayamwong E Hammack; Megan J Schmid; Matthew L LoPresti; Andre Der-Avakian; Mary Ann Pellymounter; Alan C Foster; Linda R Watkins; Steven F Maier
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.